Profilin 1 maintains cell cycle fidelity to prevent unscheduled genome doubling and polyploidy in cancer

Whole-genome doubling (WGD) represents a major route to genome instability and therapeutic resistance in cancer; yet, the mechanisms enabling genome duplication in p53-proficient cells remain poorly understood. Here, we identify Profilin 1 (PFN1) loss as a driver of WGD through impaired mitotic entry. Using FUCCI live-cell imaging and single-cell genomic profiling, we show that PFN1-deficient cells bypass mitosis and undergo endoreplication, generating tetraploid cells. Rather than undergoing stable arrest after mitotic bypass, these genome-doubled cells retain proliferative capacity and proceed through aberrant mitotic divisions, thereby amplifying genomic instability. Proteomic analyses reveal coordinated attenuation of late cell-cycle programs, including downregulation of key mitotic regulators such as CDK1, PLK1 and CKS2, consistent with impaired G2/M transition. Despite accumulating polyploidy, PFN1-knockout cells fail to activate an effective p53 tetraploidy checkpoint and display increased nuclear MDM2, promoting cell-cycle arrest evasion and chemotherapeutic resistance. We supported clinical relevance by an orthotopic osteosarcoma xenograft model, in which PFN1-deficient SaOS2 cells showed enhanced metastatic dissemination, and by pan-cancer TCGA analyses confirming a recurrent association between PFN1 loss and WGD. Together, these findings identify Profilin 1 as a safeguard of cell-cycle fidelity whose loss enables genome doubling, cellular plasticity and therapy tolerance.